EUVIMEDEUVIMED entdecken
Crossref

Plasma CAF22, a Biomarker of Neuromuscular Junction Integrity, is Associated with Risk and Earlier Onset of Statin-Associated Muscle Symptoms

Rizwan Qaisar, M Shahid Iqbal, Asima Karim, Firdos Ahmad

Cardiovascular Drugs and Therapy · 09.11.2026

DOI: 10.1007/s10557-026-07982-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 09.11.2026. Verfasst von Rizwan Qaisar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae. Die Arbeit nennt 44 Literaturangaben. Gefördert von: University of Sharjah.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Statin-associated muscle symptoms (SAMS) are a major limitation to effective lipid-lowering therapy. C-terminal agrin fragment 22 (CAF22) is a biomarker of neuromuscular junction degradation, but its role in predicting SAMS remains unclear. METHODS: In this prospective cohort study, 383 adults aged 40-60 years initiating statin therapy were followed for 12 months. Baseline plasma CAF22 was measured prior to statin initiation. Statin intolerance was defined as clinically significant muscle symptoms leading to dose modification, discontinuation, or switching. Logistic regression and Cox proportional hazards models were used to assess associations with the occurrence and timing of statin intolerance, respectively. RESULTS: Statin intolerance occurred in 17% of participants. Higher baseline CAF22 was associated with increased odds of statin intolerance (adjusted OR: 1.32, 95% CI: 1.08-1.61, p = 0.006) and earlier onset (adjusted HR: 1.38, 95% CI: 1.15-1.63, p < 0.001). The association was consistent across unadjusted and age- and sex-adjusted models. Higher handgrip strength was associated with reduced odds (OR 0.82, 95% CI 0.74-0.97, p = 0.018) and delayed onset (HR 0.80, 95% CI 0.66-0.95, p = 0.011) of intolerance. Diabetes mellitus was independently associated with both increased odds and earlier onset, while lipophilic and high-intensity statin use were associated with earlier intolerance. Other demographic and biochemical variables were not significant predictors. CONCLUSIONS: Baseline CAF22 is independently associated with the risk and timing of statin intolerance. These findings support a role for neuromuscular junction integrity in SAMS and suggest that CAF22 may represent a potential biomarker of vulnerability.

Schlagwörter

Stichwörter der Autor:innen

C‑terminal agrin fragment‑22Neuromuscular junctionStatin intoleranceStatin‑associated muscle symptomsTime‑to‑event analysis

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
  • Space Medicine Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
  • Cardiovascular Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
  • Department of Neurology and Stroke Medicine, Rehman Medical Institute, Peshawar, 25124, Pakistan.
  • Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates.
  • Space Medicine Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates.

Förderung

  • University of Sharjah

Zitieren

APA

Qaisar, R., Iqbal, M. S., Karim, A., & Ahmad, F. (2026). Plasma CAF22, a Biomarker of Neuromuscular Junction Integrity, is Associated with Risk and Earlier Onset of Statin-Associated Muscle Symptoms. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-026-07982-4

Vancouver

Qaisar R, Iqbal MS, Karim A, Ahmad F. Plasma CAF22, a Biomarker of Neuromuscular Junction Integrity, is Associated with Risk and Earlier Onset of Statin-Associated Muscle Symptoms. Cardiovascular Drugs and Therapy. 2026. doi:10.1007/s10557-026-07982-4

BibTeX
@article{Qaisar2026,
  author = {Qaisar, Rizwan and Iqbal, M Shahid and Karim, Asima and Ahmad, Firdos},
  title = {Plasma CAF22, a Biomarker of Neuromuscular Junction Integrity, is Associated with Risk and Earlier Onset of Statin-Associated Muscle Symptoms},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  doi = {10.1007/s10557-026-07982-4}
}
Kostenlos starten →